Subject: Shaw initiates coverage of Benitec with BUY and TP AUD3.00
We are pleased to advise that Shaw Stockbrocking - a leading firm with offices across Australia - has initiated coverage of Benitec with a BUY recommendation and target price of AUD3.00. The report makes the following key points:
Validation of Benitec’s ddRNAi is rapidly approaching
The technology is potentially worth tens of billions of dollars
Risk exists but is not binary as for other recent biotechs.
Please read the full report from Shaw Stockbroking
